Imported medicine pricing discrepancies in China explained

9 September 2013

Guo Jianying, a senior official with the pricing division of the National Development and Reform Commission, has cited tax, additional pricing by hospitals and bloated circulation fees as the cause of high-end imported medicine to be sold at higher prices on the mainland than in Hong Kong, reports the Chinese news agency Xinhau.

The comments, made while attending a health-themed forum sponsored by Peking University, came amid heated public debate over Hong Kong's lower prices for high-end imported pharmaceuticals than the mainland, which reportedly have lured many mainland buyers, says Xinhau.

70%-80% of drugs sold at higher prices on mainland

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >